drugset / Trial / NCT06824155
HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 consisting of an Imaging Period with 177Lu-RAD202im(imaging dose) and a Treatment Period with 177Lu-RAD202tr(treatment dose) to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
Timeline
- Start
- 2025-02-12
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-RAD202 | Protein / enzyme biologic | 370 mbq | — |